{"name":"Miltenyi Biomedicine GmbH","slug":"miltenyi-biomedicine-gmbh","ticker":"","exchange":"","domain":"miltenyibiomedicinegmbh.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"MB-CART2019.1","genericName":"MB-CART2019.1","slug":"mb-cart2019-1","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"MB-CART2019.1","genericName":"MB-CART2019.1","slug":"mb-cart2019-1","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPNC1HXzBfbVpNVG83WXQ5ekVkQmRDUXU4Tkd1WVBGNnhJRTgweVBlUWNna2IwVWZKWUdvVk1UbDlKa0Qybm5FRDZDc2pJbDhhNl9XSDA2eHVSVkdOX0VQVHBpcEtVbFRmaVZlM1NkNElxLV9UUmVxVlBYY3RHR1hBRHp1SS0zMTB3anhabGlCN2JtZzZYX000N3FsT2o?oc=5","date":"2026-03-20","type":"trial","source":"openPR.com","summary":"B-Cell Lymphomas Clinical Trial Pipeline Appears Robust With - openPR.com","headline":"B-Cell Lymphomas Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPSGhnWkIwbTRiS1BnbmdtSFhqR0QzbU4xUFQ4bnpQekdjMWdXVW1xYXVja214b2JXOGNCNV9VYVBJRDEyS0pzaGtfekxXRzZyd1M2bXpnclRMdzFYWUZvODVJSzJXcHJJUzNXRFo3ODhOQmhRc2hiMktKTDNFVjFfdUszaE8wdWFwMThDOUsxeUFyZU1XMi1Xb0dRTVFnRV9IcExRWUc5R1BZTDZjNFpObkE1TnFzdWdOQkxWcXFWSVQzLXFqNVlqMUNsUWlnUVlkOTQtU1dOUGlrN25vSXd2LUEyZDNuSGxSQVd4ZEhoRTdDM28tRmdXdzl5eHhDaG50Tzl0TWZJdW0?oc=5","date":"2025-08-27","type":"pipeline","source":"PR Newswire","summary":"Diffuse Large B-cell Lymphoma Market to Grow at a CAGR of 13% by 2034 in Leading Markets (US, EU4, UK, and Japan) | DelveInsight - PR Newswire","headline":"Diffuse Large B-cell Lymphoma Market to Grow at a CAGR of 13% by 2034 in Leading Markets (US, EU4, UK, and Japan) | Delv","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPRVd6WXpfckdJZGoxTUJaOGRyaXpqcXgzX1RSS0xmRFp6MEx5NUJqQkZfaW5rQTRSMDBJWG9mZ2ZnQUMtZl9WTkhoNFdiZ1hyekYxUXczTzhhZlZtd1ZsSWg0d2plTnZPU3pUY0xsR0g0MnQ2OGUtcXdzOExuaEhJdDNoMGRLZ0owUzZ0WHFweHZRZnlrODBud0htTzUwcndEb1A2QzdQb3dOTFBMSGM3MmJCZEVmZmthNmdibmN6MnBNYmtFLTdNSzl3X2FZSmUyN3lNemFaQ1JmNnI2dU9ZLWVMSFgyQXlzU0thSGl3ZWpDbklKbjlpelA4WEFhQTlxMzIyYlB3cHRGNWhDRnVmb0Z0NlVOSnFSU3B0Zzh0eFgtbWlGTEtlMURhNjFUd3dFMEow?oc=5","date":"2025-07-21","type":"pipeline","source":"GlobeNewswire","summary":"Cutaneous T-cell Lymphoma Market Anticipates Impressive - GlobeNewswire","headline":"Cutaneous T-cell Lymphoma Market Anticipates Impressive","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxQLUdGNExlVk1Yb25WMVhZWUlQUzgteV93WGRaSHU4WWZzMDFUYURLQXV5dFdHM3JTcERzSVQ5eUlLOFRSTXFsak8xdFJ4RmpHblB6YXJWY0tXMnhrQWluUk5OTkRqWTZvWHB0UkUyMndISW9XSS1tNDhnTDVnZmVxZm1lWUVLM3VVb2Y0dzJ2ZDExNWlhNk84RERxRkJSY2RubzhfSHZPZ3JpQ1NhSWV3ODltTlc3TF9ZWlV4LXFNWV9EdFlOT1RQNnFGeVotT3l3LWhmd2Z1Y19DcmtfQzJqdDlSaFlsZWJhWmlPMVluVkIzTmRPcTQxcDZ1UkhicGVfQUFqZ3QtZHVfTEQ1RXB4UmFkVkRmeXduUU1XQzM2YU5Jb002cnNpb01B?oc=5","date":"2024-11-28","type":"trial","source":"PR Newswire","summary":"Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therape","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQYXlpWWtJNGNLZHJEeWRMRnR6R0E2SVY5eElibzV2ZDlyaGZ0cDNLd3Z4V2hIVWpoZlA1LUw5SEd6SHRHbWNva1VQcUExU1FQN1lWV3pBN2M4aUktay16cGpCc2pPc2xsOWlwUzBvMXFGbmduaG5OdE1mZEM5aEdlN3BsNU1LNER4eWtScEpHb1hKUllUWm1OSndEM3MySmF6d3VPY0Q5ZVFjclBWUG5TMGNpODhhYWdiUlFQbV94T0g1T3RyZ2FnOWlhS0Z1c0xpNnExUGJBMTJfSGNGR01paGlveU5mazNqMV9JM1FIX1FlSzUwSjJ4VEtBWjVtWTVfTmpteW9n?oc=5","date":"2024-11-19","type":"regulatory","source":"PR Newswire","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - PR Newswire","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsigh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxQOTFNRmFOVjV3QnVlYzU5Yzhab0FEdDNpb1BiSWl6em8yUGZ5eVNveWRuMlpvNEZZTF9fR001Qmw1dFpWMEtHS2xkQUU2MkZDdVFta3pSMXdSVXhwZkdtLUg4d0NOX1NLa3Z0M0NBZnJ2Z0JvTk5kd3QzdU45N3Vqem1zX0xlSFpQQ2lBRXdFZ20xQ0NkclVRSG9odTBULTd2WVBXbEZRdkY5VHVrcWtjVXc4WXZXRzBIZzdGN2xaX2o0YWZaNUkyY0JvcWdDZ1NNZDBGVnJ5Mkc0M0k3azRiXzM0a0JRYmdQNkRLRzJqZFE0QUFQcW5WdVNYTHZKb19CQUxncW5pbEl6S2QtUWNSQnVVWGdsUQ?oc=5","date":"2024-10-21","type":"regulatory","source":"GlobeNewswire","summary":"Allogeneic Hematopoietic Stem Cell Transplant Market to - GlobeNewswire","headline":"Allogeneic Hematopoietic Stem Cell Transplant Market to","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQMU8zZVBUUXhFSnNTcHdRYjRkNTlORzQ0MmUzRkpvSkV5bHctaXRHQUNaczY5WW1JVm5NRjNaQ1hQelZtd2ZxSDZCV0RLUXJxTC1oajZkUXNYSFN3YXRwMWVMbmJJMzFPTnNxaTZfWEZyaE5wcUNISUg2M3JYS05OMzVRUk95UExSSkNJUEdzc2NKcVdNelBwTkxBOVM?oc=5","date":"2024-01-02","type":"trial","source":"Clinical Trials Arena","summary":"ASH 2023: Miltenyi Biomedicine’s MB-CART 19.1 to tackle autoimmunity - Clinical Trials Arena","headline":"ASH 2023: Miltenyi Biomedicine’s MB-CART 19.1 to tackle autoimmunity","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2022-07-21","type":"pipeline","source":"European Medical Journal","summary":"Zamtocabtagene Autoleucel (MB-CART2019.1): An Investigational CAR-T Cell Product with Tandem Targeting of CD19 and CD20 as a Potential Treatment Option for Patients with Relapsed/ Refractory B Cell No","headline":"Zamtocabtagene Autoleucel (MB-CART2019.1): An Investigational CAR-T Cell Product with Tandem Targeting of CD19 and CD20 ","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}